Table 3.
Copy number variations of mtDNA in laryngeal cancer — univariate associations with clinicopathological characteristics
| Characteristics |
Copy number <4.02 |
|
Copy number >5.42 |
|
|---|---|---|---|---|
| OR* (95% CI) | P | OR* (95% CI) | P | |
| Male vs. Female |
2.73 (0.37-20.28) |
0.33 |
1.89 (0.30-11.86) |
0.50 |
| Age |
1.00 (0.96-1.05) |
0.92 |
1.01 (0.97-1.05) |
0.78 |
| Differentiation1 |
1.02 (0.25-4.10) |
0.98 |
0.64 (0.17-3.01) |
0.64 |
| Tumor invasion2 |
1.43 (0.92-2.25) |
0.11 |
0.94 (0.60-1.46) |
0.77 |
| TNM stage3 |
1.53 (1.04-2.25) |
0.03 |
1.04 (0.71-1.51) |
0.84 |
| LNM4 |
2.31 (0.90-5.95) |
0.08 |
1.50 (0.58-3.89) |
0.41 |
| Smoking history5 |
0.46 (0.16-1.34) |
0.16 |
0.29 (0.10-0.84) |
0.02 |
| Survival status6 | 0.81 (0.36-1.84) | 0.61 | 0.79 (0.35-1.77) | 0.56 |
*OR: odds ratio with 95% confidence interval; 1Differentiation (well or moderate; poor or undifferentiation); 2Tumor invasion (T1; T2; T3; T4); 3TNM stage (I; II; III; IV); 4LNM (lymph node metastasis); 5Smoking history (at least 10 pack-years); 6Survival status (Alive vs. Dead); The cases with 4.02-5.42 mtDNA copies were used as reference.